The selectivity and specificity of the actions of the lipido-sterolic extract of serenoa repens (Permixon®) on the prostate

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 876-881

  Bayne, Colin W ^a   Ross, Margaret ^a   Donnelly, Frank ^a   Habib, Fouad K ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 reductase; Apoptosis; BPH; Cell morphology; Permixon

Indexed keywords

LIPID; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE; STEROL;

APOPTOSIS; ARTICLE; BREAST; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; DRUG SPECIFICITY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EPIDIDYMIS; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; KIDNEY; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; SKIN; TESTIS;

EID: 0033898916     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67330-2     Document Type: Article

References (31)

1. Buck, A. C.: Phytotherapy for the prostate. Br J Urol, 78: 325, 1996
2. Plosker, G. L. and Brogden, R. N.: Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Ageing, 9: 379, 1996
3. Grasso, M., Montesano, A., Buonaguidi, A. et al: Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp de Urol, 40: 97, 1995
4. Carraro, J. C., Raynaud, J. P., Koxh, G. et al: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomised international study of 1098 patients. Prostate, 29: 231, 1996
5. Wilt, T. J., Ishami, A., Stark, C. et al: Saw Palmetto extracts for treatment of benign prostatic hyperplasia. JAMA, 280: 1604, 1998
6. Boyle, P., Robertson, C., Lowe, F. et al: Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Adult Urology, 55 (in press), 2000
7. Iehle, C., Delos, S., Guirou, O. et al: Human prostatic steroid 5α-reductase isoforms. A comparative study of selective inhibitors. J. Steroid Biochem Mol Biol, 54: 273, 1995
8. Bayne, C. W., Donnelly, F., Ross, M. et al: Serenoa repens (Permixon®): a 5α-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate, 40: 232, 1999
9. Di Silverio, F., Monti, S., Martini, C. et al: Effects of long term treatment with the n-hexane lipido-sterolic extract of Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate, 37: 77, 1998
10. Carilla, E., Brieley, M., Fauran, F. et al: Binding of Permixon: a new treatment for prostatic benign hyperplasia to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem Mol Biol, 20: 521, 1984
11. Paubert-Braquet, M., Mencia-Huerta, J. M., Cousse, H. et al: Effect of the lipido-sterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol, 33: 340, 1997
12. Carraro, J-C., Raynaud, J. J., Koch, G. et al: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate, 29: 231, 1996
13. Descotes, J. L., Rambeaud, J. J., Deschaseaux, P. et al: Placebo controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest, 5: 291, 1995
14. Lowe, F., Robertson, C., Roehrborn, C. G. et al.: Meta-analysis of clinical trials of Permixon. [Abstract] J Urol, 159: 257, 1998
15. Tsugaya, M., Habib, F. K., Chisholm, G. D. et al: Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res, 24: 265, 1996
16. Habib, F. K.: Regulation of prostate growth in culture with the pollen extract, cernitin T-60 and the impact of the drug on the EGF tissue profiles. In: Benign Prostate Diseases. Edited by W. Vahlensick and G. Rutishuaser. Stuttgart; New York: Thieme Verlag, p. 120, 1992
17. Byers, S. W., Djakiew, D. and Dym, M.: Structural features of rat epididymal epithelial cells in vitro. J Reprod Fertil, 75: 401, 1985
18. Berensztein, E., Belgorosky, A. and Rivarola, M. A.: Primary culture of prepubertal human testicular cells isolated from testes collected at necropsy. Acta Endocrinol, 127: 66, 1992
19. Jen, Y-M., West, C. M. L. and Hendry, J. H.: The lower radio-sensitivity of mouse kidney cells irradicated in vivo then in vitro: a cell contact effect phenomenon. Int J Rad Oncol Biol Phys, 20: 1243, 1996
20. Brown, T. R. and Migeon, C. J.: Cultured human skin fibroblasts: a model for the study of androgen action. Mol Cell Biochem, 36: 3, 1981
21. Croce, M. V., Colussi, A. G. and Segal-Eiras, A.: Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res, 17: 19, 1998
22. Svitkina, T. M., Veskhorsky, A. B. and Bonisy, G. G.: Improved procedures for electron microscopic visualisation of the cytoskeleton of cultured cells. J Struct Biol, 115: 290, 1995
23. Bayne, C. W., Donnelly, F., Chapman, K et al: A novel co-culture model for benign prostatic hyperplasia expressing both isoforms of 5α-reductase. J Clin Endocrinol Metab, 83: 206, 1998
24. Smith, C. M., Ballard, S. A., Warman, N. et al: 5α-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia. J Clin Endocrinol Metab, 81: 1361, 1996
25. + 4-ene-oxide-reductase; EC1.3.1.22) in a stable and active form. J Steroid Biochem Mol Biol, 38: 73, 1991
26. Weisser, H. and Krieg, M.: Fatty acid composition of phospholipids in epithelium and stroma of human benign prostatic hyperplasia. Prostate, 36: 235, 1998
27. Weisser, H., Ziemssen, T. and Krieg, M.: Phospholipid requirement of 5α-reductase in human benign prostatic hyperplasia (BPH). Urol Res, 25: 73A, 1997
28. Ravenna, L., Di Silverio, F., Russo, M. et al.: Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 29: 219, 1996
29. 14C] β-sitosterol. Eur J Drug MetabPharmacokinetics, 22: 73, 1997
30. Grant, E. S., Ross, M. B., Ballard, S. et al: The insulin-like growth factor type I receptor stimulates growth and suppressed apoptosis in prostatic stromal cells. J Clin Endocr Metab, 83: 3252, 1998
31. Rouleau, M., Leger, J. and Tenniswood, M.: Ductal heterogeneity of cytokeratines gene expression and cell death in the rat ventral prostate. Mol Endocrinol, 4: 2003, 1990